FDA Continues Its Food Dye Cleanup

July 23, 2026

Reading Time : 1 min

On July 22, 2026, the Food and Drug Administration (FDA) announced two additional steps in its ongoing effort to phase out petroleum-based color additives from the U.S. food supply. Specifically, the agency issued a final order revoking the authorization for Orange B and proposed revoking the authorization for Citrus Red No. 2, both on the basis that their approved uses have been abandoned by industry. As discussed in our prior posts, FDA announced last year that it would work with industry to eliminate petroleum-based synthetic dyes by the end of 2026, and Congress has since joined the conversation with legislation targeting several commonly used food dyes.

Although neither action is expected to have a significant immediate impact on most food manufacturers, the announcement serves as another reminder that FDA continues to closely examine color additives and other food ingredients. Food and beverage companies should expect continued agency attention to synthetic dyes, color additive authorizations and related food chemical policy initiatives as FDA advances its broader regulatory agenda.

See our prior coverage of FDA’s synthetic dye phaseout announcement here, FDA’s approval of new natural color additives here and FDA’s earlier proposal to revoke Orange B here.

Share This Insight

Previous Entries

Eye on FDA

July 23, 2026

On July 22, 2026, the Food and Drug Administration (FDA) announced two additional steps in its ongoing effort to phase out petroleum-based color additives from the U.S. food supply. Specifically, the agency issued a final order revoking the authorization for Orange B and proposed revoking the authorization for Citrus Red No. 2, both on the basis that their approved uses have been abandoned by industry. As discussed in our prior posts, FDA announced last year that it would work with industry to eliminate petroleum-based synthetic dyes by the end of 2026, and Congress has since joined the conversation with legislation targeting several commonly used food dyes.

...

Read More

Eye on FDA

June 29, 2026

On June 24, 2026, the Food and Drug Administration (FDA) published a notice of availability in the Federal Register requesting information and public comment on an Expedited Investigational New Drug (IND) pilot program. The proposed pilot program is part of the Trump administration’s focus on taking steps to strengthen America’s leadership in clinical research, accelerate the development of lifesaving treatments and ensure that patients have access to the most innovative therapies in the world.

...

Read More

Eye on FDA

June 10, 2026

On June 2, 2026, the U.S. Food and Drug Administration (FDA) issued draft guidance on how drug and device companies may communicate health care economic information (HCEI) with payors (e.g., health insurance companies), formulary committees (e.g., pharmacy and therapeutics committees) and similar entities. The guidance, Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers, is now open for comment.

...

Read More

Eye on FDA

May 19, 2026

On May 12, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting comment on the agency’s efforts related to drug repurposing to help address unmet medical needs. In this request for information (RFI), FDA is seeking input to identify potential new uses for FDA-approved drugs—such as a new indication or a new population—to help accelerate the availability of treatments for unmet medical needs. Stakeholders are encouraged to submit priority disease areas and potential candidates for drug repurposing, particularly in cases where there is a lack of commercial incentive to pursue labeling changes or a significant unmet need.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.